Izraelis - hebrajų - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - methylprednisolone acetate - תרחיף להזרקה - methylprednisolone acetate 40 mg/ml - methylprednisolone - methylprednisolone - for the treatment of conditions responsive to steroid injection therapy.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - cytarabine - אבקה להכנת תמיסה לזריקה - cytarabine 1 g/vial - cytarabine - cytarabine - induction and maintenance of remission in acute myelocytic leukemia of adults and children. treatment of other leukemias.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - idarubicin hydrochloride - אבקה להכנת תמיסה מרוכזת לעירוי - idarubicin hydrochloride 10 mg/vial - idarubicin - idarubicin - antimitotic and cytotoxic agent. acute non-limphocytic leukemia (anll) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.acute limphocytic leukemia (all) as second line treatment in adults and children.

Izraelis - hebrajų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - lidocaine as hydrochloride; methylprednisolone acetate - תרחיף להזרקה - lidocaine as hydrochloride 10 mg/ml; methylprednisolone acetate 40 mg/ml - methylprednisolone, combinations - lidocaine - depo-medrol with lidocaine is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - synovitis of osteoarthritis - rheumatoid arthritis - acute and subacute bursitis - acute gouty arthritis - epicondylitis - acute nonspecific tenosynovitis - post-traumatic osteoarthritis.

Izraelis - hebrajų - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.